(Total Views: 338)
Posted On: 06/26/2025 5:04:46 AM
Post# of 154583
Ganesha, apparently it is an option, according to this question to and comment by Max Lataillade on his LinkedIn account:
To Max Lataillade:
Amazing results. Can you tell us how would these results affect the CRC trial just beginning with Leronlimab. Is it possible a similar MOA might take place there, even though CRCs don't usually greatly express PD-L1? Will they incorporate the possibility of adding a checkpoint inhibitor in that trial, depending on biomarkers?
Max Lataillade:
Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!
Celebrate
likecelebrate
14
Reply
To Max Lataillade:
Amazing results. Can you tell us how would these results affect the CRC trial just beginning with Leronlimab. Is it possible a similar MOA might take place there, even though CRCs don't usually greatly express PD-L1? Will they incorporate the possibility of adding a checkpoint inhibitor in that trial, depending on biomarkers?
Max Lataillade:
Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!
Celebrate
likecelebrate
14
Reply
(19)
(0)
